Built AI-native
An agentic operating model spanning development, regulatory, and commercial functions.
About
Proven CNS therapeutics · an agentic operating model · built to commercialize at the scale of large pharma.
Skythia Bio is an AI-native biopharmaceutical company built to commercialize CNS and brain-health therapeutics with a fraction of the headcount the industry assumes is required.
We embed agentic AI across development, regulatory, and commercial operations — not as a feature, but as the operating model — turning proven medicines into accessible treatments faster and leaner than legacy pharma.
Our focus is the brain: protecting cognition, building cognitive resilience, and extending the years people live well.
The differentiator
Skythia uses AI to bring therapies to patients faster.
A purpose-built, agentic AI infrastructure runs the work of a full commercial organization — compressing cost and timelines so more patients reach effective treatment, sooner. The result is a new kind of biopharma: small, fast, and full-stack.
Operating leverage
The output of a large commercial organization, delivered by a focused team.
Brain-health focus
Cognitive resilience, longevity, and extending healthspan.
Mission
We are the brain-health company — extending healthspan by bringing proven CNS therapeutics to the patients who need them.
Get in touch
Partner with us.
For partnership, pipeline, and investor inquiries, reach the team directly.
partners@skythia.bio